124 related articles for article (PubMed ID: 6994867)
41. Regression by active specific immunotherapy of established dermal tumor transplants and lymph node metastases in guinea pigs.
Yarkoni E; Rapp HJ
Infect Immun; 1981 Jan; 31(1):514-6. PubMed ID: 7216457
[TBL] [Abstract][Full Text] [Related]
42. A comparison of in vitro cell-mediated reactivity against syngeneic tumor cells by various lymphoid cell populations from Bacillus Calmette-Guérin-tumor-cured, tumor-sensitized, tumor-bearing, and normal inbred guinea pigs.
Fidler IJ; Kataoka T; Hanna MG
Cancer Res; 1976 Dec; 36(12):4459-66. PubMed ID: 187324
[TBL] [Abstract][Full Text] [Related]
43. Efficacy of bacillus Calmette-Guérin Strains for Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Network Meta-Analysis.
Boehm BE; Cornell JE; Wang H; Mukherjee N; Oppenheimer JS; Svatek RS
J Urol; 2017 Sep; 198(3):503-510. PubMed ID: 28286068
[TBL] [Abstract][Full Text] [Related]
44. A controlled clinical and immunological evaluation of immunotherapy with Bacillus Calmette--Guerin in patients with metastatic cancer.
O'Connell MJ; Ritts RE; Moertel CG; O'Fallon JR; Rubin J; Frytak S; Schutt AJ
Cancer Clin Trials; 1981; 4(4):439-49. PubMed ID: 6459190
[TBL] [Abstract][Full Text] [Related]
45. Experimental screening of BCG preparations produced for cancer immunotherapy: safety and immunostimulating and antitumor activity of four consecutively produced batches.
de Jong WH; Steerenberg PA; Kreeftenberg JG; Tiesjema RH; Kruizinga W; van Noorle Jansen LM; Ruitenberg EJ
Cancer Immunol Immunother; 1984; 17(1):18-27. PubMed ID: 6563941
[TBL] [Abstract][Full Text] [Related]
46. Influence of the virulence of Mycobacterium tuberculosis on protection induced by bacille Calmette-Guérin in guinea pigs.
Hank JA; Chan JK; Edwards ML; Muller D; Smith DW
J Infect Dis; 1981 May; 143(5):734-8. PubMed ID: 6787142
[TBL] [Abstract][Full Text] [Related]
47. Comparison of the adjuvant effect of three BCG preparations in mice.
Baker MA; Taub RN
Oncology; 1978; 35(5):214-6. PubMed ID: 82928
[TBL] [Abstract][Full Text] [Related]
48. Eradication of microscopic hepatic metastases by active specific immunization.
Sukumar S; Hunter JT; Terata N; Rapp HJ
Cancer Immunol Immunother; 1983; 14(3):151-4. PubMed ID: 6340824
[TBL] [Abstract][Full Text] [Related]
49. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
[TBL] [Abstract][Full Text] [Related]
50. Cellular interactions modulating host resistance to tumours.
Baldwin RW; Byers VS; Hannant D; Jones JA; Pimm MV; Price MR
Recent Results Cancer Res; 1982; 80():338-45. PubMed ID: 7036295
[TBL] [Abstract][Full Text] [Related]
51. Utilization of Bacillus Calmette-Guerin for Nonmuscle Invasive Bladder Cancer in an Era of Bacillus Calmette-Guerin Supply Shortages.
Khanna A; Yerram N; Zhu H; Kim S; Abouassaly R
Urology; 2019 Feb; 124():120-126. PubMed ID: 30219556
[TBL] [Abstract][Full Text] [Related]
52. Eradication by active specific immunotherapy of established tumor transplants and microscopic lymph node metastases.
Yarkoni E; Ashley MP; Zbar B; Sugimoto T; Rapp HJ
Cancer Res; 1982 Jul; 42(7):2544-6. PubMed ID: 7083146
[TBL] [Abstract][Full Text] [Related]
53. Does switching the bacillus Calmette-Guérin strain affect clinical outcome in patients with recurrent non-muscle-invasive bladder cancer after initial bacillus Calmette-Guérin therapy?
Niwa N; Kikuchi E; Matsumoto K; Kosaka T; Mizuno R; Oya M
Urol Oncol; 2018 Jun; 36(6):306.e1-306.e8. PubMed ID: 29530465
[TBL] [Abstract][Full Text] [Related]
54. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
[TBL] [Abstract][Full Text] [Related]
55. Intratumor immunochemotherapy with 5-fluorouracil emulsion and BCG in C3H/HE mice transplanted with MH134.
Sakita M; Kasuga M; Yamane T; Torii T; Imai H; Kageyama N; Fujita Y; Majima S
Gan; 1982 Dec; 73(6):931-7. PubMed ID: 6761229
[TBL] [Abstract][Full Text] [Related]
56. Therapy of spontaneous metastases with an autologous tumor vaccine in a guinea pig model.
Hoover HC; Peters LC; Brandhorst JS; Hanna MG
J Surg Res; 1981 Apr; 30(4):409-15. PubMed ID: 7230788
[No Abstract] [Full Text] [Related]
57. Intravesical bacillus Calmette-Guerin (BCG) instillation for primary and recurring T1G3 bladder cancers.
Okamura T; Akita H; Ando R; Kawai Y; Tozawa K; Kohri K
Asian Pac J Cancer Prev; 2010; 11(4):1107-10. PubMed ID: 21133632
[TBL] [Abstract][Full Text] [Related]
58. Immunotherapy of metastatic cancer in guinea pigs: failure of intralesional BCG to influence the results of radical surgery.
Hunter JT; Okuda T; Rapp HJ
J Natl Cancer Inst; 1977 Nov; 59(5):1435-9. PubMed ID: 909107
[TBL] [Abstract][Full Text] [Related]
59. Prognostic value of MIB-1 antibody labeling index to predict response to Bacillus Calmette-Guérin therapy in a high-risk selected population of patients with stage T1 grade G3 bladder cancer.
Lebret T; Becette V; Hervé JM; Molinié V; Barré P; Lugagne PM; Gentille A; Baglin AC; Botto H
Eur Urol; 2000 Jun; 37(6):654-9. PubMed ID: 10828663
[TBL] [Abstract][Full Text] [Related]
60. Prognostic significance of Bacillus Calmette-Guérin failure classification in non-muscle-invasive bladder cancer.
Shirakawa H; Kikuchi E; Tanaka N; Matsumoto K; Miyajima A; Nakamura S; Oya M
BJU Int; 2012 Sep; 110(6 Pt B):E216-21. PubMed ID: 22313616
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
